Suppr超能文献

儿童 4-7 岁人群使用破伤风类毒素-白喉(Td)疫苗:世界卫生组织专家协商会。

Use of tetanus-diphtheria (Td) vaccine in children 4-7 years of age: World Health Organization consultation of experts.

机构信息

World Health Organization, 20 Appia Avenue, Geneva, Switzerland.

Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta GA, USA.

出版信息

Vaccine. 2020 May 6;38(21):3800-3807. doi: 10.1016/j.vaccine.2020.01.018. Epub 2020 Jan 23.

Abstract

For lifetime protection against diphtheria and tetanus, the World Health Organization (WHO) recommends six doses of diphtheria and tetanus containing vaccines. Td (reduced diphtheria toxoid, ≥2-5 IU) vaccines are currently licensed for ages 7 years and older, but use of Td vaccine for ages 4 years and older would have advantages for immunization programs in many low- and middle-income countries. For this reason, WHO convened an expert consultation to review the currently available evidence for the use of Td vaccine from 4 to 7 years of age which concluded: (1) no relevant biological difference in immune response in the relevant age group compared with children over 7 years of age; (2) adequate seroprotection in several studies with Td vaccine in the 4-7 age group and many studies using combination vaccines; (3) durable and protective response of at least 9-11 years duration in several longitudinal and modelling studies, (4) less reactogenicity compared with use of full-dose diphtheria vaccine, potentially improving the vaccination experience; and (5) adequate control of diphtheria in several countries using Td-containing combination vaccines in 4-7 year old children. On this basis, the experts concluded that from a programmatic perspective, Td vaccine given in ages 4-7 years, as a second booster dose in a six-dose series, would provide adequate protection against diphtheria and tetanus and recommended steps to include this change in age extension listed in the package insert.

摘要

为了终生预防白喉和破伤风,世界卫生组织(WHO)建议接种六剂含白喉和破伤风类毒素的疫苗。目前,Td(降低白喉毒素,≥2-5IU)疫苗获准用于 7 岁及以上人群,但在 4 岁及以上人群中使用 Td 疫苗对许多中低收入国家的免疫规划具有优势。为此,世卫组织召集了一次专家协商会议,以审查目前可用于 4 至 7 岁儿童的 Td 疫苗使用情况,该会议得出结论:(1)在相关年龄组与 7 岁以上儿童相比,免疫反应没有明显的生物学差异;(2)在 4-7 岁年龄组使用 Td 疫苗和许多使用联合疫苗的研究中,均有足够的血清保护率;(3)在几项纵向和建模研究中,至少有 9-11 年的持久和保护反应;(4)与使用全剂量白喉疫苗相比,反应原性较低,可能改善接种体验;(5)在几个国家中,使用 Td 含联合疫苗在 4-7 岁儿童中,对白喉的控制效果良好。在此基础上,专家们得出结论,从规划角度来看,在 4-7 岁年龄组接种 Td 疫苗,作为六剂系列中的第二剂加强针,将提供对白喉和破伤风的充分保护,并建议在接种说明书中列入将这一年龄组扩大的步骤。

相似文献

本文引用的文献

3
Off-label use of vaccines.疫苗的非标签使用。
Vaccine. 2017 Apr 25;35(18):2329-2337. doi: 10.1016/j.vaccine.2017.02.056. Epub 2017 Mar 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验